HC Wainwright Has Positive Estimate for KPTI FY2024 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a research note issued on Tuesday, November 5th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($1.06) for the year, up from their previous forecast of ($1.07). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.06) EPS and FY2026 earnings at ($0.53) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period last year, the firm earned ($0.30) EPS.

KPTI has been the subject of a number of other research reports. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Piper Sandler lifted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Trading Down 0.6 %

Shares of KPTI opened at $0.88 on Friday. The company’s fifty day simple moving average is $0.81 and its 200 day simple moving average is $0.90. Karyopharm Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.95. The company has a market cap of $109.88 million, a price-to-earnings ratio of -0.77 and a beta of 0.16.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors have recently made changes to their positions in KPTI. Ikarian Capital LLC boosted its stake in Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $31,000. Exchange Traded Concepts LLC boosted its position in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after acquiring an additional 56,613 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics in the second quarter valued at about $143,000. Finally, Acadian Asset Management LLC bought a new position in Karyopharm Therapeutics during the second quarter worth about $167,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).